

Primary gastric lymphoma and spontaneous remission associated with co-infection of COVID-19 and undefined typical bacterial agent.

Gaukhar Kurmanova

Al-Farabi Kazakh National University

Yerkebulan Bossatbekov (✉ rotfl.lol@mail.ru)

Al-Farabi Kazakh National University

Zhanna Alimanova

Al-Farabi Kazakh National University

Sholpan Tankayeva

Al-Farabi Kazakh National University

Akbota Bugibaeva

Al-Farabi Kazakh National University

Abhishek Sarawata

Al-Farabi Kazakh National University

Kajal Singh

Al-Farabi Kazakh National University

Fuza Adhur Manhuvalappa Abbas

Al-Farabi Kazakh National University

Neetu Singh

Al-Farabi Kazakh National University

Case Report

Keywords: Primary gastric lymphoma, non-Hodgkins $lymphoma$, $Hodgk \in s$ lymphoma, SARS-CoV 2, COVID-19

Posted Date: May 10th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1629520/v2>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: A case report underlines a clinical experience of a patient with primary gastric lymphoma disease. The article demonstrates reduction of the lymphoproliferative disorder to the spontaneous remission, after community-acquired pneumonia with co-infection of COVID-19, and undefined typical bacterial agent. A positive response has gone through a period of COVID-19 condition and appeared ongoing the standard antibacterial and basic symptomatically treatment.

Case presentation: A 65-years-old woman was admitted by ambulance to the emergency department with sever condition. In time of hospitalization, the patient has diagnosed with ulcer form of primary gastric lymphoma with signs of ongoing capillary bleeding, thrombocytopenic syndrome, normochromic anaemia, diabetes militias type 2 with complication of hypoglycaemic condition associated with metformin, and chronic bronchitis. The data laboratory and instrumental investigations confirmed the condition.

Conclusion: The article underlines extremely positive response up to disappearing of ulcer form of primary gastric lymphoproliferative disorder. The condition associated with anti-tumor effect of highly cytokines production because of COVID-19 and undefined typical bacterial agent.

Background

Primary gastric lymphoma (PGL) is an uncommon condition, accounting for less than 15% of gastric malignancies and about 2% of all lymphomas¹. The stomach is a more common extra nodal site for lymphomas. It means for lymphomas originate elsewhere and metastasis to the stomach². It is also the most common source of lymphomas in the gastrointestinal tract³.

SARS-CoV 2 is a strain of coronavirus that causes COVID-19. It is the main respiratory illness responsible for the ongoing COVID-19 pandemic, which started registration since 2019⁴.

In the article, a clinical experience gives a description of the patient with PGL. The data information of esophagogastroduodenoscopy (EGD) and stomach biopsy established primary gastric lymphoproliferative disorder. Also case demonstrate reduction of the lymphoma condition after community-acquired pneumonia associated with co-infection of COVID-19 and undefined typical bacterial agent, and positive response ongoing standard antibacterial and basic symptomatically treatment. The remission has observed of the diseases condition during coronavirus disease (COVID-19). It compared with similar experience from other countries between other cases of Hodking's lymphoma, non-Hodking`s lymphoma, and H.pylori.

Case Presentation

A 65-years-old woman was admitted by ambulance to the emergency department with complaints of dizziness, nausea, bruisers in the body, severe general weakness, malaise, appetite loss, fainting, general

weakness in October 2020. It was a time of first hospitalization. According to the case history information it provides proof of no presence and past medical history of oncology and other several diseases, except diabetes mellitus type 2. She has received metformin (oral route) 1000 mg once a day. The data information of the patient presented in EGD with stomach biopsy and Chest X-ray (CXR) in October 2020, which shows morphological picture of gastric lymphoproliferative disorder and chronic bronchitis. In time of discharging, laboratory investigations indicated cytopenic syndrome of 3 cells lines in complete blood count (CBC) with red blood cells (RBC) count of $2,42 \times 10^{12}/L$ (reference range $3,9-4,7 \times 10^{12}/L$), hemoglobin (Hb) of 76 g/L (reference range 115-160 g/L), mean corpuscular volume (MCV) of 97,9 fL (reference range 80-100 fL), white blood cells (WBC) count of $3,55 \times 10^9/L$ (reference range $4,0-9,0 \times 10^9/L$) including lymphocytes count of 13,2% (reference range 20-40%) and absolute lymphocytes count (ALC) of $0,47 \times 10^9/L$ (reference range $0,8-5,0 \times 10^9/L$). Inflammation markers and acute phase protein indicated increasing C-reactive protein (C-RP) of 16,5 mg/L (reference range 0-5,0 mg/L) and D-dimer of 21,19 (reference range 0-0,5 mg/L). Other laboratory data were in the reference ranges (Figure 1). The patient has no doubt diagnosed with severe condition ulcer form of PGL with signs of ongoing capillary bleeding, chronic bronchitis, diabetes mellitus type 2 complicated hypoglycaemic condition associated with metformin, thrombocytopenic syndrome, normochromic anaemia. The patient has received basically and symptomatically treatment: ciprofloxacin 200 mg / 100 mL two times a day intravenous injection for 13 days, omeprazole (oral route) 20mg two times a day, 40% glucose solution 20 mL once a day intravenously for 2 days; and 5% glucose solution 500 mL once a day intravenously for 3 days, correction with metformin (oral route) dose from 1000 mg to 500 mg once a day for 5 days. At last, the patient was discharged with disease stabilization and slightly positive response to get a consultation from an oncologist for initiate specific treatment – immunochemical treatment in October 2020.

In time of outpatient care, the patient has not received the consultation from the oncologist. Next hospitalization condition ongoing in January 2021, after 2 months of previous hospitalization. The patient was hospitalized with the same complaints, and addition of respiratory distress. The condition transformed to PGL and community-acquired pneumonia with co-infection of COVID-19 and undefined bacterial agents. The data information of co-infection confirmed by CXR and lungs computer tomography (CT) scan. CXR shows right sided multisegmented pneumonia, which were on the right in the middle and lower zone of the lungs and infiltrative opacification contours. CT scan of the lungs shows right sided upper lobe pneumonia and pulmonary fibrosis on both sides. A pulmonary fibrosis notes along the periphery, fibrous cords, and infiltration of upper lobe on the right. (Figure 2, 3). Laboratory and other instrumental investigations were scheduled for differential diagnosis and excluding complication of PGL. Laboratory data demonstrate bacterial infection activity into the patient, CBC indicates WBC of $14,89 \times 10^9/L$ including segmented neutrophils of 90,5% (reference ranges 40-60%), absolute neutrophils count (ANC) of $13,47 \times 10^9/L$ ($2,5-7,0 \times 10^9/L$), lymphocytes of 13,2%, ALC of $0,47 \times 10^9/L$ (Figure 1); inflammation markers indicate C-RP of 653.5 mg/L, D-dimer of 1,74 mg/L, erythrocyte sedimentation rates (ESR) of 75 mm/H (reference range 0-20 mm/H), fibrinogen of 7,74 g/L (reference range 2,0-4,0 g/L), other laboratory data were in reference ranges. Specific tests, which include polymerase chain reaction (PCR) of SARS-CoV 2 nasopharyngeal test, and ELISA of SARS-CoV2 ratio of immunoglobulin M

(IgM), immunoglobulins G (IgG), TB microscopic, Xpert MTB/RIF, culturology of sputum, established negative result. EGD repeated and showed chronic superficial gastritis with no gastric lymphoproliferative ulcer and other severe pathology process. The patient management consists of antibiotics and symptomatic treatment: cefotaxime 1 g four times a day intravenously injection for 7 days, azithromycin (oral route) 500 mg once a day for 5 days, omeprazole (oral route) 20 mg once a day for 10 days, 0,9% normal saline 500 mL with 5% vitamin C 6,0 mL intravenously for 3 days, enoxaparine 30 mg / 0,3 mL twice a day subcutaneously for 10 days. The patient has not received glucocorticoids (GCS) and immunochemical treatment. She has discharged with highly positive effect with no specific treatment of PGL, and COVID-19. The laboratory dynamic of patient condition illustrates highly positive immune response with faster decreasing of inflammatory markers (Figure 1). The main pathophysiology process identified as a resemble of PGL remission and reliving from co-infection of COVID-19 and undefined typical bacterial agent.

Discussion

As noted in British Society for Haematology with SARS-CoV-2-induced remission of Hodgkin's lymphoma. The theory of the pathophysiology action mechanism includes cross-reactivity of pathogen-specific T-cells⁵. The mechanism pointed to way cross-reactivity, it is described in non-Hodkin's lymphoma with anti-tumor immune response after concurrent infection⁶.

SARS-CoV-2 uses the viral spike (S) protein for host-cell attachment and entry through binding of ACE-2 (angiotensin-converting enzyme 2)⁷. It is important action mechanism of the pathology process into cells, which may be the clue of the case explanation in the patient situation. As known, the other bacterial infection like *H. pylori* may regulate gastric inflammation and associated cytokines by ACE-2⁸.

Conclusion

As has been shown, the case points to the outcome of standard treatment with no specific action, which resembles mechanism of provoking cytokine releasing in consequence of co-infection: COVID-19 and undefined typical bacterial agent. The affecting of co-infection could enable attracting tumor microenvironment (TME) immune cells. In terms of action mechanism position, which include cross-reactivity of pathogen – specific T-cells with tumor antigens and natural killer (NK) cells activation by inflammatory cytokines produced in response to infection. The actions may account for the anti-tumor effect sufficient.

In summary, the patient had specifically extremely positive response up to disappearing of primary gastric lymphoma ulcer form. On the one hand, decompensation and inevitable negative effect of patient condition were expected. On the other hand, the condition demonstrated reliving from undefined typical bacterial pathogen and spontaneous remission of lymphoma without specific treatment of lymphoproliferative disorder.

Declarations

Ethics approval and consent to participate

The study since all data are completely anonymous. The patient consented to the use of anonymous data.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal

Competing interests

The authors declare that they have no competing interests

Funding

Not applicable

Acknowledgements

Not applicable

Authors' contributions

1. Kurmanova Gaukhar Medeubaevna has explained whole patient condition and remission, from position of immunology, oncology and hematology.
2. Yerkebulan Nurlanovich Bossatbekov lead the patient in the hospitalization time and pointed the case situation, also design the work.
3. Zhanna Maxutovna Alimanova has explained whole patient condition and remission, as general practitioner, and has led the patient at first hospitalization time.
4. Sholpan Abilkassimovna Tankayeva has analyzed the situation by differential diagnosis criteria, as a pulmonologist from the respiratory diseases.
5. Bugibaeva Akbota Berdalievna has helped with review of the case condition, interpreted data analysis
6. Abhishek Sarawata, Kajal Singh, Fuza Adhur Manhuvalappa Abbas, Neetu Singh are students, who helped to analyze data base information of laboratory and instrumental investigation, they prepared figures

Authors' information

1. Kurmanova Gaukhar Medeubaevna

Ph.D, professor, head of Higher School Medicine education program, Al-Farabi Kazakh National University, Almaty city, Kazakhstan.

ORCID ID 0000-0002-5768-0209.

Email: gkurman@mail.ru

2. Bossatbekov Yerkebulan Nurlanovich

Lecture of Higher School Medicine education program, general practitioner, Al-Farabi Kazakh National University, Almaty city, Kazakhstan.

ORCID ID 0000-0001-6563-9567

Email: rotfl.lol@mail.ru

3. Alimanova Zhanna Maxutovna

Docent of Higher School Medicine education program, general practitioner with cardiology addition, Al-Farabi Kazakh National University, Almaty city, Kazakhstan.

ORCID ID 0000-0003-2419-8931

Email: zhanna_danik@mail.ru

4. Tankayeva Sholpan Abilkassimovna

Lecturer of Higher School Medicine education program, general practitioner, Al-Farabi Kazakh National University, Almaty city, Kazakhstan.

ORCID ID 0000-0002-4260-9653

Email: sholpantank@gmail.com

5. Bugibaeva Akbota Berdalievna

Master of Higher School Medicine education program, general practitioner, Al-Farabi Kazakh National University, Almaty city, Kazakhstan.

ORCID ID 0000-0003-1417-271

Email: bota_88.20@mail.com

6. Abhishek Sarawata

Student of Higher School Medicine education program, Al-Farabi Kazakh National University, Almaty city, Kazakhstan.

Email: abhisheksarawata32@gmail.com

7. Kajal Singh

Student of Higher School Medicine education program, Al-Farabi Kazakh National University, Almaty city, Kazakhstan.

Email: kajal220499@gmail.com

8. Adhur Manhuvalappa Fuza Abbas

Student of Higher School Medicine education program, Al-Farabi Kazakh National University, Almaty city, Kazakhstan.

Email: fuzaabdulla@gmail.com

9. Neetu Singh

Student of Higher School Medicine education program, Al-Farabi Kazakh National University, Almaty city, Kazakhstan.

Email: neetusingh3574@gmail.com

References

- [1] Dawson IM, Cornes JS, Morson BC. (1961) Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. *Br J Surg.* 49 (213): 80-9. doi: 10.1002/bjs.18004921319. PMID 13884035.
- 2 Aisenberg AC. (1995). Coherent view of non-Hodgkin's lymphoma. *J. Clin. Oncol.* 13 (10): 2656–75. doi:10.1200/JCO.1995.13.10.2656. PMID 7595720.
- 3 Koch P, del Valle F, Berdel WE. (2001). "Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92". *J. Clin. Oncol.* 19 (18): 3861–73. doi:10.1200/JCO.2001.19.18.3861. PMID 11559724.
- 4 Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. (2020) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it

SARS-CoV-2. *Nature Microbiology*. 5 (4): 536–544. doi:10.1038/s41564-020-0695-z. PMC 7095448. PMID 32123347.

5 Sarah Challenor and David Tucker. (2021) SARS-CoV-2-induced remission of Hodgkin lymphoma. doi: 10.1111/bjh.17116 PMID: 33386647.

6 Buckner TW, Dunphy C, Fedoriw YD, van Deventer HW, Foster MC, Richards KL. (2012) Complete spontaneous remission of diffuse large B-cell lymphoma of the maxillary sinus after concurrent infections. *Clinical Lymphoma, Myeloma & Leukemia*. doi: 10.1016/j.clml.2012.06.007 PMID: 23025990

7 Shang J, Wan Y, Luo C. (2020) Cell entry mechanisms of SARS-CoV-2. *Proc Natl Acad Sci U S A*. <https://doi.org/10.1073/pnas.2003138117>

8 Stacy Carl-McGrath, Ilona Gräntzdörffer, Uwe Lendeckel, Matthias P Ebert, Christoph Röcken. (2009) Angiotensin II-generating enzymes, angiotensin-converting enzyme (ACE) and mast cell chymase (CMA1), in gastric inflammation may be regulated by *H. pylori* and associated cytokines. *Pathology, the journal of the Royal College of Pathologists of Australia*. doi: 10.1080/00313020902885037 PMID: 19424904

Figures

Figure 1

RBC – Red blood cells, Hb – Hemoglobin, MCV – Mean corpuscular volume, WBC – White blood cells, PLT – Platelets, Htc – hematocrit, ANC - Absolute neutrophil count, ALC - Absolute lymphocyte count, CRP – C-reactive protein, ESR – Erythrocyte sedimentation rates, PCT – Procalcitonin.

Figure 2

Red arrows show right sided upper lobe pneumonia and pulmonary fibrosis on both sides of the lungs. A pulmonary fibrosis notes along the periphery, fibrous cords, and infiltration of upper lobe on the right.

Figure 3

Red arrows show right sided upper lobe pneumonia and pulmonary fibrosis on both sides of the lungs. A pulmonary fibrosis notes along the periphery, fibrous cords, and infiltration of upper lobe on the right.